Inhibitors for the soluble epoxide hydrolase

Details Inhibitors for the soluble epoxide hydrolase Inhibitors for the soluble epoxide hydrolase

2005-10-20

2010-02-16

Kosar, Andrew D (Department: 1654)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

C514S002600

Reexamination Certificate

active

07662910

ABSTRACT:
Inhibitors of the soluble epoxide hydrolase (sEH) are provided that incorporate multiple pharmacophores and are useful in the treatment of diseases.

REFERENCES:
patent: 3587060 (1971-06-01), Quinn et al.
patent: 3703537 (1972-11-01), Richter et al.
patent: 3755415 (1973-08-01), Richter et al.
patent: 4252954 (1981-02-01), Abdulla et al.
patent: 5273982 (1993-12-01), Alig et al.
patent: 5314902 (1994-05-01), Tjoeng et al.
patent: 5445956 (1995-08-01), Hammock et al.
patent: 5637113 (1997-06-01), Tartaglia et al.
patent: 5877224 (1999-03-01), Brocchini et al.
patent: 5962455 (1999-10-01), Blum et al.
patent: 6150415 (2000-11-01), Hammock et al.
patent: 6287285 (2001-09-01), Michal et al.
patent: 6290722 (2001-09-01), Wang
patent: 6299604 (2001-10-01), Ragheb et al.
patent: 6322847 (2001-11-01), Zhong et al.
patent: 6329395 (2001-12-01), Dugar et al.
patent: 6335029 (2002-01-01), Kamath et al.
patent: 6344358 (2002-02-01), Matsuoka et al.
patent: 6351506 (2002-02-01), Lewicki
patent: 6444691 (2002-09-01), Oremus et al.
patent: 6531506 (2003-03-01), Kroetz et al.
patent: 6562849 (2003-05-01), Fujita et al.
patent: 6613572 (2003-09-01), Matsuoka et al.
patent: 6710043 (2004-03-01), Yamada et al.
patent: 2002/0090732 (2002-07-01), Matsuoka et al.
patent: 2003/0078426 (2003-04-01), Fujita et al.
patent: 2004/0014745 (2004-01-01), Yamada et al.
patent: 2004/0054187 (2004-03-01), Mammen et al.
patent: 2004/0092487 (2004-05-01), Kroetz et al.
patent: 2005/0026844 (2005-02-01), Hammock et al.
patent: 2005/0164951 (2005-07-01), Hammock et al.
patent: 2007/0225283 (2007-09-01), Hammock et al.
patent: 2 360 360 (2000-07-01), None
patent: 123 466 (1976-12-01), None
patent: 0 503 627 (1992-09-01), None
patent: 1 031 564 (2000-08-01), None
patent: 1167366 (2002-01-01), None
patent: 4-13666 (1992-01-01), None
patent: 7-133224 (1995-05-01), None
patent: 2001-158789 (2001-06-01), None
patent: 2002179568 (2002-06-01), None
patent: 2003-522120 (2003-07-01), None
patent: 2004-002414 (2004-01-01), None
patent: 2 208 608 (2003-07-01), None
patent: WO 99/07700 (1999-02-01), None
patent: WO 99/09024 (1999-02-01), None
patent: WO 9932437 (1999-07-01), None
patent: WO 00/42011 (2000-07-01), None
patent: WO 00/48593 (2000-08-01), None
patent: WO 0061581 (2000-10-01), None
patent: WO 00/72834 (2000-12-01), None
patent: WO 00/72834 (2000-12-01), None
patent: WO 00/76457 (2000-12-01), None
patent: WO 00/76457 (2000-12-01), None
patent: WO 01/42212 (2001-06-01), None
patent: WO 02/14311 (2002-02-01), None
patent: WO 02/14311 (2002-02-01), None
patent: WO 03/009845 (2003-02-01), None
patent: WO 03/061597 (2003-07-01), None
patent: WO 03/061597 (2003-07-01), None
patent: WO 03/070242 (2003-08-01), None
patent: WO 03/070727 (2003-08-01), None
patent: WO 03/076426 (2003-09-01), None
patent: WO 03/076426 (2003-09-01), None
patent: WO 03/082861 (2003-10-01), None
patent: WO 03/082861 (2003-10-01), None
patent: WO 03/097586 (2003-11-01), None
patent: WO 03/097618 (2003-11-01), None
patent: WO 2004/007459 (2004-01-01), None
patent: WO 2004/007459 (2004-01-01), None
patent: WO 2004/026836 (2004-04-01), None
patent: WO 2004/026836 (2004-04-01), None
patent: WO 2004/063181 (2004-07-01), None
patent: WO 2004/064730 (2004-08-01), None
patent: WO 2004/064730 (2004-08-01), None
patent: WO 2004/089296 (2004-10-01), None
patent: WO 2004/094381 (2004-11-01), None
patent: WO 2004/111009 (2004-12-01), None
patent: WO 2004/111031 (2004-12-01), None
patent: WO 2005/014580 (2005-02-01), None
patent: WO 2005/030209 (2005-04-01), None
patent: WO 2005/037199 (2005-04-01), None
patent: WO 2005/037199 (2005-04-01), None
patent: WO 2005/089763 (2005-09-01), None
patent: WO 2005/113511 (2005-12-01), None
patent: WO 2006/009741 (2006-01-01), None
patent: WO 2006/014136 (2006-02-01), None
patent: WO 2006/014359 (2006-02-01), None
patent: WO 2006/014359 (2006-02-01), None
patent: WO 2006/016039 (2006-02-01), None
patent: WO 2006/045119 (2006-04-01), None
Arand, M. et al., “Sequence similarity of mammalian epoxide hydrolases to the bacterial haloalkane dehalogenase and other related proteins” FEBS Lett., 338:251-256 (1994).
Argiriadi, M.A. et al., “Binding of alkylurea inhibitors to epoxide hydrolase implicates active site tyrosines in substrate activation” J. Biol. Chem., 275:15265-15270 (2000).
Argiriadi, M.A. et al., “Detoxification of encironmental mutagens and carcinogens: structure, mechanism, and evolution of liver epoxide hydrolase” Proc. Natl. Acad. Sci. USA, 96:10637-10642 (1999).
Bardin, C. W. (ed.),Current Therapy In Endocrinology and Metabolism, 6th Edition, Mosby—Year Book, Inc., St. Louis, MO 1997.
Beetham, J. et al., “cDNA cloning and expression of a soluble epoxide hydrolase from human liver” Arch. Biochem. Biophys., 305(1):197-201 (1993).
Beetham, J. et al., “Gene evolution of epoxide hydrolases and recommended nomenclature” DNA Cell Biol., 14(1):61-71 (1995).
Campbell, W.B., “New role for epoxyeicosatrienoic acids as anti-inflammatory mediators” Trends Pharmacol. Sci., 21:125-127 (2000).
Capdevila, J.H. et al., “Cytochrome P450 and arachidonic acid bioactivation: molecular and functional properties of the arachidonate monooxygenase” J. Lipid. Res., 41:163-181 (2000).
Carroll, M.A. et al., “A new class of lipid mediators: cytochrome P450 arachidonate metabolites” Thorax, 55:S13-16 (2000).
Chiasson, J. et al., “The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus” Ann. Intern. Med., 121:928-935 (1994).
Coniff, R. et al., “Multicenter, placebo-controlled trial comparing acarbose (BAY g5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus” Am. J. Med., 98:443-451 (1995).
Coniff, R. et al., “Acarbose: a review of US clinical experience” Clin. Ther., 19:16-26 (1997).
Defronzo, R. et al. (eds.), “Introduction” Diabetes Reviews, 5(4):293 (1997).
Dudda, A. et al., “Lipid oxidation products in ischemic porcine heart tissue” Chem. Phys. Lipids, 82:39-51 (1996).
Fang, X., et al., “Effect of soluble epoxide hydrolase inhibition on epoxyeicosatrienoic acid metabolism in human blood vessels” Am. J. Physiol. Heart Circ. Physiol. 287:H2412-H2420 (2004).
Fisslthaler, B. et al., “Cytochrome P450 2C is an EDHF synthase in coronary arteries” Nature, 401:493-497 (1999).
Fretland, A.J. et al., “Epoxide hyrolases: biochemistry and molecular biology” Chem. Biol. Intereract., 129:41-59 (2000).
Fukushima, A. et al., “Cardiovascular effects of leukotoxin (9,10-epoxy-12-octadecenoate) and free fatty acids in dogs” Cardiovasc. Res., 22:213-218 (1988).
Gibson, G.G. and Skett, P.,Introduction to Drug Metabolism, Second Ed., Chapman and Hall, New York pp. 199-210 (1994).
Grant, D. et al., “Molecular cloning and expression of murine liver soluble epoxide hydrolase” J. Biol. Chem., 268(23):17628-17633 (1993).
Haffner, S., “Management of dyslipidemia in adults with diabetes” Diabetes Care, 21:160-178 (1998).
Hammock, B.D. et al., “Chapter 3.18: Epoxide Hyrolases” inComprehensive Toxicology. Oxford: Pergamon Press pp. 283-305 (1977).
Honig and Ingram, “Chronic Bronchitis, Emphysema, and Airways Obstruction” inHarrison's Principles of Internal Medicine, (Fauci et al., Eds.), 14th Ed., McGraw-Hill, New York, pp. 1451-1460 (1998).
Hwang, S. et al., “Orally Bioavailable Potent Soluble Epoxide Hydrolase Inhibitors” J. Medicinal Chemistry, pp. A-P (2007).
Ishizaki, T. et al., “Leukotoxin, 9,10-epoxy-12-octadecenoate causes pulmonary vasodilation in rats” Am. J. Physiol., 268:L123-128 (1995).
Ishizaki, T. et al., “Leukotoxin, 9,10-epoxy-12-octadecenoate causes edematous lung injury via activation of vascular nitric oxide synthase” Am. J. Physiol., 269:L65-70 (1995).
Ishizaki, T. et al., “Endothelin-1 potentiates leukotoxin-indu

Affiliated with

Also associated with

Rating

Inhibitors for the soluble epoxide hydrolase does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inhibitors for the soluble epoxide hydrolase, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors for the soluble epoxide hydrolase will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4153017